Macarena Oporto Espuelas, Saskia Burridge, Amy A Kirkwood, Denise Bonney, Kelly Watts, Geoff Shenton, Katarzyna A Jalowiec, Maeve A O'Reilly, Claire Roddie, Anna Castleton, Katherine Clesham, Emma Nicholson, Rajesh Alajangi, Shilpa Prabhu, Lindsay George, Ben Uttenthal, Maria Gabelli, Lorna Neill, Caroline Besley, Sridhar Chaganti, Robert F Wynn, Jack Bartram, Robert Chiesa, Giovanna Lucchini, Vesna Pavasovic, Anupama Rao, Kanchan Rao, Juliana Silva, Sujith Samarasinghe, Ajay Vora, Peter Clark, Michelle Cummins, David I Marks, Persis Amrolia, Rachael Hough, Sara Ghorashian
CAR T-cell therapy has transformed relapsed/refractory (r/r) B-cell precursor acute lymphoblastic leukaemia (B-ALL) management and outcomes, but following CAR T infusion, interventions are often needed. In a UK multicentre study, we retrospectively evaluated tisagenlecleucel outcomes in all eligible patients, analysing overall survival (OS) and event-free survival (EFS) with standard and stringent definitions, the latter including measurable residual disease (MRD) emergence and further anti-leukaemic therapy...
April 15, 2024: Blood Cancer Journal